Table 2 (A) Characteristics of controlled studies. (B) Outcomes of controlled studies.
From: Transalveolar sinus floor lift without bone grafting in atrophic maxilla: A meta-analysis
(A) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | Year | Study type | Country | Inclusion Period | Patients | Initial RBH | ImplantLength (mm) | Graft materials in grafting group | Healing time (Months) | Measurement Instrument | Follow-up (Months) | |
NG | G | |||||||||||
Lai HC | 2010 | PS | China | 2003–2008 | 202 | 5.6 ± 2.5 mm | 4.7 ± 2.1 mm | 6/8/10 | alloplastic bone-replacing material, β-tricalcium phosphate Cerasorb® mixed with autogenous bone chips | NG: 3-4 G:6-8 | PaR, PR | Range: 12–60 |
Marković A | 2016 | RCT | Spain | 2011–2012 | 45 | 6.59 ± 0.45 mm | 10 | β-tricalcium phosphate (β-TCP), deproteinized bovine bone (DBB), or their combination | 6 | CBCT | 29.7 | |
Nedir R | 2013, 2016, 2017 | RCT | Switzerland | 2007–2009 | 12 | 2.6 ± 0.9 mm | 2.2 ± 0.8 mm | 8 | inorganic bovine spongiosa bone mineral Bio-Oss® | 2.6 ± 0.9 | PaR | 12, 36, and 60 |
Pjetursson BE | 2009 | PS | Switzerland | 2000–2005 | 181 | 8.1 ± 2.1 mm | 6.4 ± 1.9 mm | 6/8/10/12 | deproteinized bovine bone mineral Bio-Oss® | 4–6 | PaR | 38.4 Range: 12–84 |
Si MS | 2013 | RCT | China | 2007–2011 | 41 | 4.58 ± 1.47 mm | 4.67 ± 1.18 mm | 6/8/10 | deproteinized bovine bone mineral (DBBM) mixed with autogenous bone chips | 6 | PR | 36 |
Verdugo F | 2017 | PS | Italy | — | 27 | 4.5 ± 0.8 mm | 3.8 ± 1.2 mm | 8/10/11.5 | autogenous cortical bone particles | 3–4 | CBCT | Range: 36–144 |
(B) | ||||||||||||
Study | Year | Implant number | EsBG (mm) | MBL (mm) | Survival rate | |||||||
NG | G | NG | G | NG | G | NG | G | |||||
Lai HC | 2010 | 191 | 89 | — | — | — | — | 97.38% | 92.13% | |||
Marković A | 2015 | 45 | 135 | — | — | — | — | 100% | 100% | |||
Nedir R | 2013 | 17 | 20 | 3.9 ± 1.0 | 5.0 ± 1.3 | 0.6 ± 0.8 | 0.4 ± 0.7 | 100% | 90% | |||
2016 | 4.1 ± 1.0 | 5.1 ± 1.2 | 0.6 ± 1.1 | 0.5 ± 1.0 | 94.1% | 90% | ||||||
2017 | 3.8±1.0 | 4.8 ± 1.2 | 0.6 ± 0.9 | 0.7 ± 1.4 | 94.1% | 90% | ||||||
Pjetursson BE | 2009 | 164 | 88 | 1.7 ± 2 | 4.1 ± 2.4 | — | — | 97.56% | 97.72% | |||
Si MS | 2013 | 20 | 21 | 6 months: 2.06 ± 1.01; 12 months: 2.45 ± 0.98; 24 months: 3.12 ± 0.70; 36 months: 3.07 ± 1.68 | 6 months: 5.66 ± 0.99; 12 months: 3.56 ± 1.82 24 months: 3.02 ± 0.48 36 months: 3.17 ± 1.95 | 6 months: 0.67 ± 0.92; 12 months: 1.28 ± 0.05; 24 months: 1.32 ± 0.45; 36 months: 1.38 ± 0.23 | 6 months: 0.21 ± 0.23; 12 months: 0.44 ± 0.16; 24 months: 0.65 ± 0.30; 36 months: 1.33 ± 0.46 | 95.0% | 95.2% | |||
Verdugo F | 2017 | 14 | 13 | 6.8 ± 0.5 | 8.5 ± 1.9 | 0.9 ± 0.6 | 0.8 ± 0.7 | 100% | 100% | |||
